Please login to the form below

Not currently logged in
Email:
Password:

Eagle Genomics appoints executive chairman

Anthony Finbow replaces Alan Barrell

Eagle Genomics Anthony FinbowUK-based Eagle Genomics has appointed Anthony Finbow as its new executive chairman.

He succeeds Alan Barrell in the role, with Barrell becoming a non-executive director at the life sciences research firm.

Finbow had previously been working in an advisory capacity at Eagle Genomics, assisting chief executive officer Abel Ureta-Vidal with business development.

Ureta-Vidal said: “Anthony's arrival has been transformative for Eagle Genomics. He has been pushing the boundaries of the business and the management team to come up with innovative products opening up unsuspected opportunities.

“I am happy to have him my side and I'm confident that the coming years will be the most exciting for the Eagle Genomics business.”

Finbow brings over 20 years of senior leadership experience to the firm, and currently serves as chief executive officer at Solv Ltd, a leadership development business.

He has worked at several software firms, including Orchestream where he was chief executive officer and MetaSolv Software as its managing director.

He said: “I am delighted to have been invited to become executive chairman at Eagle Genomics at this formative stage in the company's development.

“In the short time that I have been involved with the business, we have achieved exciting progress, including the securing of our most significant software sale to date and the development, with launch customers, of a new family of products, to be announced shortly.”

13th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics